



Advanced platelet-rich fibrin promotes the paracrine function and proliferation of adipose-derived stem cells and contributes to micro-autologous fat transplantation by modulating *HIF-1 α* and *VEGF*

Hao Huang^{1#}, Xike Tang^{2#}, Shounan Li³, Donglin Huang⁴, Dongchangcheng Lu⁵, Fuzhi Wu⁵, Dalie Liu¹, Hongmian Li⁶

¹Department of Plastic and Aesthetic Surgery, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China; ²Dermatology Department, The Affiliated Nanning Infectious Disease Hospital of Guangxi Medical University and the Fourth People's Hospital of Nanning, Nanning, China; ³Department of Thoracic Surgery, the People's Hospital of Binyang County, Nanning, China; ⁴Department of Plastic and Aesthetic Surgery, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning, China; ⁵Nanning Wilking Biological Technology Co., Ltd., Nanning, China; ⁶Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning, China

Contributions: (I) Conception and design: H Huang, S Li; (II) Administrative support: X Tang, D Huang; (III) Provision of study materials or patients: D Lu; (IV) Collection and assembly of data: D Lu, F Wu, X Tang; (V) Data analysis and interpretation: D Huang, D Liu, H Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work and should be considered as co-first author.

Correspondence to: Doctor Dalie Liu. Department of Plastic and Aesthetic Surgery, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510282, China. Email: liudalie1955@163.com; Doctor Hongmian Li. Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region & Guangxi Academy of Medical Sciences, Nanning 530021, China. Email: lihongmian@gxmu.edu.cn.

Background: The micro-autologous fat transplantation (MAFT) technique has demonstrated its feasibility in multiple medical fields, such as facial rejuvenation. Advanced platelet-rich fibrin (*APRF*), an autologous platelet concentrated on a fibrin membrane without added external factors, has shown significant potential for tissue restoration. However, the role of *APRF* in the modulation of MAFT remains unclear. Here, we aimed to explore the effect of *APRF* on MAFT.

Methods: Adipose-derived stem cells (ASCs) were isolated from human gastric subcutaneous fat and treated with *APRF*. ELISA assays measured cytokines. The proliferation of ASCs was analyzed by CCK-8 assays. The levels of hypoxia-inducible factor-1 α (*HIF-1 α*), heat shock protein 70 (*HSP70*), insulin like growth factor 2 (*IGF-2*), interleukin-6 (*IL-6*), interleukin-8 (*IL-8*), and vascular endothelial growth factor (*VEGF*) were measured by ELISA assays, quantitative reverse transcription-PCR (qRT-PCR), and Western blot analysis. The effect of *APRF/HIF-1 α /VEGF* on MAFT *in vivo* was analyzed in Balb/c nude mice. The BALB/c mice were subcutaneously co-transplanted with fat, *APRF*, and control shRNA, *HIF-1 α* shRNA, or *VEGF* shRNA into the dorsal area. The serum and protein levels of the above cytokines were analyzed by ELISA assays and Western blot analysis. Lipid accumulation was measured by Oil Red O staining. The expression of CD34 was assessed by immunohistochemical staining.

Results: *APRF* continuously secreted multiple cytokines, including epidermal growth factor (*EGF*), FGF-2, insulin like growth factor 1 (*IGF-1*), interleukin-1beta (*IL-1 β*), interleukin-4 (*IL-4*), platelet-derived growth factor alpha polypeptide b (*PDGF-AB*), platelet-derived growth factor beta polypeptide b (*PDGF-BB*), transforming growth factor-beta (*TGF- β*), and *VEGF*. *APRF* was able to promote the proliferation of ASCs. *APRF* dose-dependently activated the expression of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs. *APRF* regulated the paracrine function of ASCs by modulating *HIF-1 α* and *VEGF*. *APRF* increased the survival of MAFT by modulating *HIF-1 α* and *VEGF* *in vivo*.

Conclusions: *APRF* promotes the paracrine function and proliferation of ASCs and contributes to MAFT by modulating *HIF-1 α* and *VEGF*. Our findings provide new insights into the mechanism by which *APRF* regulates MAFT.

Keywords: Micro-autologous fat transplantation (MAFT); adipose-derived stem cells (ASCs); paracrine; advanced platelet-rich fibrin (*APRF*); hypoxia-inducible factor-1 α (*HIF-1 α*); vascular endothelial growth factor (*VEGF*)

Submitted Nov 12, 2021. Accepted for publication Jan 05, 2022.

doi: 10.21037/atm-21-6812

View this article at: <https://dx.doi.org/10.21037/atm-21-6812>

Introduction

Fat is a repeatedly accessible, host-compatible, readily available, abundant, inexpensive, and autologous filler that restores volume (1). Fat generally holds stem cells, and fat grafting potentially increases the character of the overlying skin and restores skin injuries, thereby restoring the face. Fat is regarded as preferable to temporary conventional fillers (2). A significant limitation of fat transplantation is the uncertainty of surgeons concerning its application, owing to the changeable and variable incidence of graft survival (3). Due to better knowledge of adipose tissue elements developed over the last decade, operators can ultimately predict each segment's function to adjust procedures, which increases the yield of targeted cells and enhances clinical outcomes (4). Unpredictable retention rates and morbidities of fat grafting have been reported, such as neurovascular injury, abscess, nodulation, and cyst formation (5). Structural fat grafting has gained widespread attention and has exhibited satisfactory clinical outcomes (6). The traditional surgical excision of fat mass or dermal fat mass transplantation has significant trauma, large surgical scar and may cause the defect of the donor area. micro-autologous fat transplantation (MAFT) can reduce the transplantation trauma, and there is no noticeable scar in the donor and recipient area. MAFT will make the shape of the receiving area uniform and natural, without body surface shadow and easy to shape (7-9). The theory of MAFT has been proposed, and the reliability of nodulation in facial rejuvenation has been validated (6,10-12). However, it was found that the graft survival rate of simple transplantation of granular adipocytes was poor. Tang et al found that the adipose stem cells can significantly increase the expression of basic fibroblast growth factor, improve the microcirculation of grafts, and significantly improve

the morphology and function of granulosa adipocytes (13). However, the modulation mechanism of MAFT is still poorly understood.

It has been shown that advanced platelet-rich fibrin (*APRF*), a concentrate of autologous platelets on a fibrin membrane without added external factors, presents significant potential for tissue restoration (14). *APRF* affects soft and bone tissue regeneration by the presence of monocytes/macrophages and their respective growth factors (15-17). The abundant platelets contained in *APRF* progressively release a high concentration of cytokines and growth factors, including vascular endothelial growth factor (*VEGF*), insulin-like growth factor-1 (*IGF-1*), and platelet-derived growth factor (PDGF), contributing to fat tissue engineering (18). However, the role of *APRF* in the modulation of MAFT remains elusive.

Hypoxia is described as a mismatch of cellular oxygen demand and supply. It is a feature of multiple diseases due to high proliferative rates, increased metabolism, and poor vascularization (19). The response to hypoxia is mainly mediated by the stabilization of hypoxia-related genes, such as hypoxia-inducible factor-1 α (*HIF-1 α*), which transcriptionally activates over 300 genes (20). It has been reported that HIF signalling is involved in the modulation of fat transplantation (21), and *VEGF* contributes to fat transplantation (22). However, the correlation of these factors with *APRF* in the regulation of MAFT is still unclear.

In this study, we aimed to explore the role and underlying mechanism of *APRF* in manipulating MAFT. We identified a novel function of *APRF* in contributing to MAFT by regulating *HIF-1 α* and *VEGF*.

We present the following article following the ARRIVE reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6812/rc>).

Methods

Extraction and collection of APRF

We selected three healthy adult volunteers (20 mL per volunteer) venous blood was collected. After blood collection, it was put into 4 glass coated sterile negative pressure plastic tubes without anticoagulants. After centrifugation at 1,500 rpm for 14 minutes and rest for 5 minutes, we obtained 3 separation layers in the test tube. Discard the supernatant and cut off the longitudinal red end of the *APRF* layer to ensure that all red blood cell components were completely removed. Then, the *APRF* The extract of (*APRF*e) was stored at 4 °C. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The present study was approved by the Institutional Review Board of the Fifth Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, China) (No. 2019-107-01). Written informed consent was provided by the donor patients.

ASC isolation, culture, and identification

Human gastric subcutaneous fat was obtained from excess tissues removed during reconstructive and plastic surgery. ASCs were isolated as previously reported (23-25). Briefly, adipose tissues were washed with phosphate-buffered saline (PBS) 3 times, cut into small pieces, and the extracellular matrixes were digested using collagenase solution (0.1%) with shaking (40 minutes, 37 °C). After adding Dulbecco's Modified Eagle Medium (DMEM) containing 1% penicillin and 10% fetal bovine serum (FBS), the cell pellets were centrifuged (3 minutes, 1,600 rpm). The debris was removed, and the cells were cultured. The cells were cultured in DMEM (Gibco, Carlsbad, California, USA) containing 10% FBS (Gibco, Carlsbad, California, USA), 0.1 mg/mL streptomycin (Gibco, Carlsbad, California, USA), and 100 units/mL penicillin (Gibco, Carlsbad, California, USA) at 37 °C with 5% CO₂. The Ethics Review Board of Zhujiang Hospital, Southern Medical University/ The Second School of Clinical Medicine, Southern Medical University approved the investigation concerning human participants. All cases provided written consent to participate in the research. *APRF* was obtained from Sangon Biotech (Sangon Biotech, Shanghai, China). *HIF-1α* shRNA, *VEGF* shRNA, and control shRNA were obtained from GenePharma (Shanghai, China).

We isolated adipose-derived stem cells (ASCs) from adipose tissue samples obtained from 1 healthy female volunteer who underwent abdominal liposuction

(24 years old, 163 cm, 58 kg). Adipose tissue was digested with type I collagenase and P0 cells were extracted. To assess the ability of cells to differentiate into multiple lineages, we cultured p3-hasc in DMEM for 2–3 weeks. After that, we performed flow cytometry. The levels of cytokines secreted from *APRF* were analyzed by ELISA assays using the human epidermal growth factor (*EGF*) ELISA Kit (Elabscience, Shanghai, China), Human bEGF ELISA Kit (Elabscience, Shanghai, China), human *IGF-1* ELISA Kit (Boster, Wuhan, Hubei, China), human interleukin-1beta (*IL-1β*) ELISA Kit (Elabscience, Shanghai, China), human interleukin-4 (*IL-4*) ELISA Kit (Elabscience, Shanghai, China), human platelet-derived growth factor alpha polypeptide b (PDGF-AB) ELISA Kit (Elabscience, Shanghai, China), human platelet-derived growth factor beta polypeptide b (PDGF-BB) ELISA Kit (Elabscience, Shanghai, China), human transforming growth factor-beta (*TGF-β*) ELISA Kit (Mlbio, Shanghai, China), and human *VEGF* ELISA Kit (Mlbio, Shanghai, China).

Effect of APRF on ASC proliferation and paracrine function in vitro

ASCs were harvested at the third passage and cultured in 96-well plates at a concentration of 2×10^4 cells per well in a growth culture medium (24 wells per group). 24 hours later, cells were treated for up to 7 days with basal media (BM, control) or 1 of the following 5 types of *APRF* media: BM plus 1.25% *APRF*, BM plus 2.5% *APRF*, BM plus 5% *APRF*, BM plus 10% *APRF*, and BM plus 20% *APRF*. The proliferation of ASCs was assessed using the cell counting kit-8 (CCK-8) assay (Kumamoto, Japan) and absorbance was measured at 450 nm using a microplate scanning spectrophotometer (ELx800, BioTek). The levels of cytokines in the culture medium were analyzed by ELISA assays, including the *HIF-1α* ELISA Kit (Elabscience, Shanghai, China), heat shock protein 70 (*HSP70*) ELISA Kit (Elabscience, Shanghai, China), Human *IGF-2* ELISA Kit (Boster, Wuhan, Hubei, China), Human interleukin-6 (*IL-6*) ELISA Kit (Elabscience, Shanghai, China), Human interleukin-8 (*IL-8*) ELISA Kit (Elabscience, Shanghai, China), and Human *VEGF* ELISA Kit (Mlbio, Shanghai, China).

Quantitative reverse transcription-PCR (qRT-PCR)

Total RNA was extracted by TRIZOL (Invitrogen, Carlsbad, California, USA) from the tissues and cells. First-strand cDNA was synthesized using the Strand cDNA

Synthesis Kit (Thermo, Waltham, MA, USA) as per the manufacturer's instructions. The qRT-PCR assays were carried out using the SYBR Real-time PCR I kit (Takara, Biotechnology Co., Ltd., Japan). The standard control for mRNA was glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Quantitative determination of the RNA levels was conducted by the SYBR GreenPremix Ex Taq™ II Kit (TaKaRa, Biotechnology Co., Ltd., Japan). The experiments were independently repeated at least three times. The primer sequences are as follows:

HIF-1 α forward: 5'-AGAGCAGGAAAAGGAGTC-3';
HIF-1 α reverse:
 5'-TGTACGCTTGAAAAAGTGAACCA-3';
HSP70 forward: 5'-TTTCAGTGTGTCCAGTGC-3';
HSP70 reverse: 5'-TGGTTGGTCCATCTTTTT-3';
IGF-2 forward: 5'-AAGTCCGAGAGGGACGT-3';
IGF-2 reverse: 5'-CTTGGGTGGGTAGAGCA-3';
IL-6 forward: 5'-TTCGGTCCAGTTGCCTTCT-3';
IL-6 reverse: 5'-CTGCCAGTGCCTCTTTGCT-3';
IL-8 forward: 5'-ATACTCCAAACCTTTCCACC-3';
IL-8 reverse: 5'-TCAAAAACCTTCTCCACAACC-3';
VEGF forward: 5'-AACTTTTTCGTCCAACCT-3';
VEGF reverse: 5'-TCTTCCTTCTCTTCTTCC-3';
GAPDH forward:
 5'-AGAAGGCTGGGGCTCATTTG-3';
GAPDH reverse:
 5'-AGGGGCCATCCACAGTCTTC-3'.

Western blot analysis

Total proteins were extracted from the cells or mouse tissues with RIPA buffer (CST, Waltham, MA, USA). Protein concentrations were measured using the BCA Protein Quantification Kit (Abbkine, California, USA). Equivalent concentrations of protein were separated by SDS-PAGE (12% polyacrylamide gels) and transferred to PVDF membranes (Millipore, Waltham, MA, USA) in the subsequent step. The membranes were blocked with 5% milk and incubated overnight at 4 °C with primary antibodies for *HIF-1 α* (Abcam, Massachusetts, USA), *HSP70* (Abcam, Massachusetts, USA), *IGF-2* (Abcam, Massachusetts, USA), *IL-6* (Abcam, Massachusetts, USA), *IL-8* (Abcam, Massachusetts, USA), *VEGF* (Abcam, Massachusetts, USA), and *GAPDH* (Abcam, Massachusetts, USA), where *GAPDH* served as the control. Membranes were then incubated with the corresponding secondary antibodies (Abcam, Massachusetts, USA) for 1 hour at room temperature, followed by visualization using an

Odyssey CLx Infrared Imaging System.

Analysis of MAFT *in vivo*

The effects of *APRF/HIF-1 α /VEGF* on MAFT *in vivo* were analyzed in Balb/c nude mice (250–300 g, female, 4 weeks old, n=3). The BALB/c mice were subcutaneously co-transplanted with fat, *APRF*, and control shRNA, *HIF-1 α* shRNA, or *VEGF* shRNA into the dorsal area. At 3 months after the operation, the transplanted fat tissues were harvested, weighed, and fixed for further analysis, and fat retention was calculated. The serum levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* were analyzed by ELISA assays. The protein expression levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the fat tissues of the mice were measured by Western blot analysis. Lipid accumulation was measured by Oil Red O staining. The expression of CD34 was assessed by immunohistochemical staining. Ethical approval to report this study involving animals was obtained from the Fifth Affiliated Hospital of Guangxi Medical University (2018-058-01), in compliance with the Fifth Affiliated Hospital of Guangxi Medical University guidelines for the care and use of animals.

Statistical analysis

Data were presented as mean \pm SD, and statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, The North Parker, USA). The unpaired Student's *t*-test was used to compare two groups, and one-way ANOVA to compare multiple groups. $P < 0.05$ was considered as statistically significant.

Results

APRF continuously secretes multiple cytokines

A diagram of the *APRF* preparation process is shown in *Figure 1*. To assess the potential effect of *APRF* on the paracrine function of ASCs, the cytokines secreted from *APRF* were measured by ELISA assays. We found that *APRF* continuously secreted multiple cytokines, including *EGF* (*Figure 2A*), *FGF-2* (*Figure 2B*), *IGF-1* (*Figure 2C*), *IL-4* (*Figure 2D*), *PDGF-AB* (*Figure 2E*), *PDGF-BB* (*Figure 2F*), and *VEGF* (*Figure 2G*), where day 7 showed the highest secretion. Moreover, CCK-8 assays showed that *APRF* treatment promoted the proliferation of ASCs in a dose-dependent manner (*Figure 2H*).




Figure 1 Diagram of the preparation process of *APRF*. *APRF*, advanced platelet-rich fibrin.

APRF promotes the paracrine function of ASCs

It has been identified that HIF signalling is involved in the modulation of ASCs (26). Accordingly, we explored the effect of *APRF* on HIF signalling in ASCs. ELISA assays revealed that *APRF* treatment dose-dependently enhanced the levels of *HIF-1 α* in the culture medium of ASCs (Figure 3A). Furthermore, the level of *HSP70* in the culture medium of ASCs was increased by *APRF* treatment in a dose-dependent manner (Figure 3B). *APRF* treatment was also able to induce the levels of *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in a dose-dependent manner in the culture medium of ASCs (Figure 3C-3F). Moreover, qRT-PCR assays showed that *APRF* treatment dose-dependently promoted the expression of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs (Figure 3G-3L). Similarly, Western blot analysis revealed that the protein levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs were up-regulated by *APRF* in a dose-dependent manner (Figure 3M-3R). Together, these data suggest that *APRF* can promote the paracrine function of ASCs.

APRF regulates the paracrine function of ASCs by modulating *HIF-1 α* and *VEGF*

We further investigated the role of *HIF-1 α* and *VEGF* in the modulation of ASCs. To this end, ASCs were treated with lentivirus vectors carrying the shRNA of *HIF-1 α* and *VEGF*. The efficiency of shRNAs of *HIF-1 α* and *VEGF* was

validated in ASCs, and shRNA-1 of *HIF-1 α* and shRNA-2 of *VEGF* presented more obvious effects and were therefore used in the subsequent experiments (Figure 4A,4B). ELISA assays showed that *APRF* treatment enhanced the levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the culture medium of ASCs, while depletion of *HIF-1 α* or *VEGF* was able to reverse this enhancement (Figure 4C-4H). Moreover, depletion of *HIF-1 α* or *VEGF* blocked the *APRF*-increased mRNA expression of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs (Figure 4I-4N). Similarly, the protein expression of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* induced by *APRF* treatment was reduced by *HIF-1 α* or *VEGF* depletion in ASCs (Figure 4O-4T). Together, these findings indicate that *APRF* regulates the paracrine function of ASCs by modulating *HIF-1 α* and *VEGF*.

APRF contributes to MAFT *in vivo*

Next, we aimed to explore the effect of *APRF* on MAFT *in vivo*. To this end, the BALB/c mice were transplanted with fat, co-transplanted with fat and ASCs or *APRF*, or co-transplanted with fat, ASCs, and *APRF*. We found that *APRF* treatment enhanced fat retention *in vivo* after transplantation (Figure 5A,5B). Moreover, *APRF* treatment was able to up-regulate the serum levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* (Figure 5C-5H). Similarly, the protein expression levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the fat tissues of the mice were increased by *APRF* treatment (Figure 5I-5N). Furthermore, Oil Red O staining revealed that *APRF* could promote lipid accumulation in the mice (Figure 5O, $\times 100$). Immunohistochemical staining revealed that *APRF* treatment was able to enhance the expression of CD34 in the fat tissues of the mice (Figure 5P, $\times 100$). Together, these data suggest that *APRF* contributes to MAFT *in vivo*.

APRF promotes MAFT by modulating *HIF-1 α* and *VEGF* *in vivo*

We further explored whether *HIF-1 α* and *VEGF* were involved in *APRF*-mediated MAFT *in vivo*. To this end, the BALB/c mice were co-transplanted with fat, *APRF*, and control shRNA, *HIF-1 α* shRNA, or *VEGF* shRNA. Remarkably, depletion of *HIF-1 α* or *VEGF* could attenuate *APRF* treatment-enhanced fat retention *in vivo* after transplantation (Figure 6A,6B). Moreover, *HIF-1 α* or *VEGF* knockdown could reduce the *APRF*-induced levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the




Figure 2 APRF continuously secretes multiple cytokines. The secretion of *EGF* (A), *FGF-2* (B), *IGF-1* (C), *IL-4* (D), *PDGF-AB* (E), *PDGF-BB* (F), and *VEGF* (G) from *APRF* was analyzed by ELISA assays. (H) ASCs were treated with *APRF* at the indicated dose. The cell proliferation of ASCs was analyzed by CCK-8 assays at the indicated time. *APRF*, advanced platelet-rich fibrin; *EGF*, epidermal growth factor; *IGF-1*, insulin-like growth factor-1; *PDGF*, platelet-derived growth factor; *TGF- β* , transforming growth factor-beta; *VEGF*, vascular endothelial growth factor; ASCs, adipose-derived stem cells.

serum of the mice (Figure 6C-6H). Similarly, the protein expression levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the fat tissues of the mice increased by *APRF* treatment were inhibited by *HIF-1 α* or *VEGF* depletion (Figure 6I-6N). Furthermore, Oil Red O staining revealed that *HIF-1 α* or *VEGF* depletion could decrease *APRF*-enhanced lipid accumulation in the mice (Figure 6O, $\times 100$). Immunohistochemical staining revealed that the *APRF*-increased expression of CD34 in the fat tissues of the mice was blocked by depletion of *HIF-1 α* or *VEGF* (Figure 6P, $\times 100$). Together, these data suggest that *APRF* promotes the paracrine function *in vivo* and contributes to MAFT by modulating *HIF-1 α* and *VEGF*.

Discussion

As an autologous platelet concentrate, *APRF* has been demonstrated to play a role in the modulation of fat grafting. It has been reported that *APRF* increases survival after fat grafting by regulating collagen production, inhibiting apoptosis, and promoting adipogenesis and angiogenesis (27). *APRF* and platelet-rich plasma improve fat graft outcomes (28). Nano fat-derived stem cells with *APRF* enhance skin rejuvenation and facial shape improvement following structural autologous fat transplantation (29). Autogenous-free fat grafting combined with *APRF* recovers

firm mandibular osteoradionecrosis (30). *APRF* and the adjuvant stromal vascular fraction (SVF) application for autologous fat tissue transplantation have been reported (31). In this study, we firstly identified that *APRF* promoted the paracrine function and proliferation of ASCs. We also found that *APRF* contributed to MAFT *in vivo*. These data present a novel function of *APRF* in the modulation of MAFT, providing valuable evidence for the fundamental role of *APRF* in fat grafting.

Furthermore, it has been identified that HIF signaling is involved in the modulation of fat grafting. CD54⁺ rabbit ASCs overexpressing *HIF-1 α* enhanced vascularized fat flap regeneration (21). The *Wnt*/ β -catenin and *HIF-1 α* signalling pathways were shown to be involved in the protective effect of losartan on fatty liver graft with ischemia/reperfusion injury (32). Hypoxia improves the proliferation of human ASCs by activating *HIF-1 α* (33). Moreover, it has been reported that SVF cells combined with sustained-release *VEGF*/Ang-1-PLGA microspheres enhance the survival of fat grafts in mice (34). Recipient-site preconditioning with deferoxamine promotes fat graft survival through stimulating neovascularization and *VEGF* *in vivo* (35). *VEGF*-transfected ASCs improved the survival of autologous fat transplantation (36). *VEGF*-PLA nano-sustained release microspheres and SVF enhanced the survival of autologous human fat transplantation (37). Our




Figure 3 *APRF* promotes the paracrine function of ASCs. (A-R) ASCs were treated with *APRF* at the indicated dose. (A-F) The levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the culture medium of ASCs were analyzed by ELISA assays at the indicated dose. (G-L) The mRNA expression levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs were measured by qRT-PCR assays. (M-R) The protein expression levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs were measured by Western blot analysis. The results of Western blot analysis were quantified by ImageJ software. Data are presented as mean \pm SD. Significant differences are indicated by *, $P < 0.05$; **, $P < 0.01$. *APRF*, advanced platelet-rich fibrin; ASCs, adipose-derived stem cells; *HIF-1α*, hypoxia-inducible factor-1 α ; *VEGF*, vascular endothelial growth factor; qRT-PCR, quantitative reverse transcription-PCR.




Figure 4 *APRF* regulates the paracrine function of ASCs by modulating *HIF-1α* and *VEGF*. (A,B) ASCs were treated with lentivirus vectors carrying the shRNA of *HIF-1α* and *VEGF*. The efficiency of shRNAs of *HIF-1α* and *VEGF* was validated by qRT-PCR assays in ASCs. (C-T) ASCs were treated with *APRF*, or co-treated with *APRF* and the shRNA of *HIF-1α* or *VEGF*. (C-H) The levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the culture medium of ASCs were analyzed by ELISA assays at the indicated dose. (I-N) The mRNA expression levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in ASCs were measured by qRT-PCR assays. (O-T) The protein expression levels of *HIF-1α*, *HSP70*, *IL-6*, *IL-8*, and *VEGF* in ASCs were measured by Western blot analysis. The results of Western blot analysis were quantified by ImageJ software. Data are presented as mean ± SD. Significant differences are indicated by *, P<0.05; **, P<0.01; ###, P<0.001. *APRF*, advanced platelet-rich fibrin; ASCs, adipose-derived stem cells; *HIF-1α*, hypoxia-inducible factor-1α; *VEGF*, vascular endothelial growth factor; qRT-PCR, quantitative reverse transcription-PCR.




Figure 5 *APRF* contributes to micro-autologous fat transplantation *in vivo*. (A-P) BALB/c mice (n=3) were transplanted with fat, co-transplanted with fat and ASCs or *APRF*, or co-transplanted with fat, ASCs, and *APRF* as indicated. (A) Representative images of transplanted fat in mice. (B) The fat retention rate was calculated. (C-H) The serum levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* were analyzed by ELISA assays. (I-N) The protein expression levels of *HIF-1α*, *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the fat tissues of the mice were measured by Western blot analysis. The results of Western blot analysis were quantified by ImageJ software. (O) Lipid accumulation was measured by Oil Red O staining. (P) The expression of CD34 was assessed by immunohistochemical staining. Data are presented as mean ± SD. Significant differences are indicated by **, $P < 0.01$. *APRF*, advanced platelet-rich fibrin; ASCs, adipose-derived stem cells; *HIF-1α*, hypoxia-inducible factor-1α; *VEGF*, vascular endothelial growth factor.




Figure 6 APRF promotes micro-autologous fat transplantation by modulating *HIF-1 α* and *VEGF* *in vivo*. (A-P) BALB/c mice (n=3) were co-transplanted with fat, ASCs, APRF, and control shRNA, *HIF-1 α* shRNA, or *VEGF* shRNA. (A,B) Representative images of transplanted fat in the mice. (B) The fat retention rate was calculated. (C-H) The serum levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* were analyzed by ELISA assays. (I-N) The protein expression levels of *HIF-1 α* , *HSP70*, *IGF-2*, *IL-6*, *IL-8*, and *VEGF* in the fat tissues of the mice were measured by Western blot analysis. The results of Western blot analysis were quantified by ImageJ software. (O) Lipid accumulation was measured by Oil Red O staining. (P) The expression of CD34 was assessed by immunohistochemical staining. Data are presented as mean \pm SD. Significant differences are indicated by *, $P < 0.05$; **, $P < 0.01$. APRF, advanced platelet-rich fibrin; *HIF-1 α* , hypoxia-inducible factor-1 α ; *VEGF*, vascular endothelial growth factor.

mechanical investigation further demonstrated that *APRF* regulated the paracrine function of ASCs by modulating *HIF-1 α* and *VEGF*. *APRF* promoted MAFT by modulating *HIF-1 α* and *VEGF* *in vivo*. These data highlight an unreported role of *HIF-1 α* and *VEGF* in *APRF*-mediated ASC paracrine function and fat transplantation, identifying a new correlation of *APRF* with *HIF-1 α* and *VEGF*.

Adipocytes secrete more than 100 factors, contributing to the expression of growth factors and cytokines such as adiponectin, IGF, fibroblast growth factor (FGF), and *VEGF* (38). PDGF, *FGF-2*, and *VEGF* are tyrosine kinase receptor-mediated growth factors that have been shown to improve fat graft transplantation (38). It has been reported that MAFT is correlated with platelet-rich plasma (PRP), which includes multiple angiogenic growth factors such as *FGF*, *VEGF*, *EGF*, *TGF- β* , and PDGF (39). This technique has been shown to increase the proliferation of adipocyte-derived stem cells and enhance overall graft survival *in vitro* and *in vivo* (39). Our data showed that *APRF* induced the secretion of *EGF*, *FGF-2*, *IGF-1*, *IL-1 β* , *IL-4*, *PDGF-AB*, *PDGF-BB*, *TGF- β* , and *VEGF* in the culture medium of ASCs. These data provide new evidence that these factors are crucial for *APRF*-regulated paracrine functioning.

In conclusion, we discovered that *APRF* promoted the paracrine function and proliferation of ASCs, and contributed to MAFT by modulating *HIF-1 α* and *VEGF*. Our findings provide new insights into the mechanism by which *APRF* regulates MAFT.

Acknowledgments

Funding: This work was financially supported by the National Nature Science Foundation of China (81760346), the Guangxi Natural Science Foundation (2018GXNSFAA281148), the Scientific Research & Technology Development Program of Nanning (20183037-1, 20191034), the Yong River Program of Innovation and Entrepreneurship of Nanning (2018-01-07), and the Youth Science Innovation and Entrepreneurship Talent Training Project of Nanning (RC20190206).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6812/rc>

Data Sharing Statement: Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6812/dss>

[com/article/view/10.21037/atm-21-6812/dss](https://atm.amegroups.com/article/view/10.21037/atm-21-6812/dss)

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6812/coif>). HL reports that this work was financially supported by the National Nature Science Foundation of China (81760346), the Guangxi Natural Science Foundation (2018GXNSFAA281148), the Scientific Research & Technology Development Program of Nanning (20183037-1, 20191034), the Yong River Program of innovation and entrepreneurship of Nanning (2018-01-07), the Youth Science Innovation and Entrepreneurship Talent Training Project of Nanning (RC20190206), of which the authors are greatly appreciative. DL and FW are from Nanning Wilking Biological Technology Co., Ltd. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The present study was approved by the Institutional Review Board of the Fifth Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, China) (No. 2019-107-01). Written informed consent was provided by the donor patients. Ethical approval to report this study involving animals was obtained from the Fifth Affiliated Hospital of Guangxi Medical University (No. 2018-058-01), in compliance with the Fifth Affiliated Hospital of Guangxi Medical University guidelines for the care and use of animals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Ozer K, Colak O. Micro-Autologous Fat Transplantation Combined With Platelet-Rich Plasma for Facial Filling

- and Regeneration: A Clinical Perspective in the Shadow of Evidence-Based Medicine. *J Craniofac Surg* 2019;30:672-7.
2. Pu LLQ. Fat Grafting for Facial Rejuvenation and Contouring: A Rationalized Approach. *Ann Plast Surg* 2018;81:S102-8.
 3. Coleman SR, Katzel EB. Fat Grafting for Facial Filling and Regeneration. *Clin Plast Surg* 2015;42:289-300, vii.
 4. Huang SH, Lin YN, Lee SS, et al. Three Simple Steps for Refining Transcutaneous Lower Blepharoplasty for Aging Eyelids: The Indispensability of Micro-Autologous Fat Transplantation. *Aesthet Surg J* 2019;39:1163-77.
 5. Strong AL, Cederna PS, Rubin JP, et al. The Current State of Fat Grafting: A Review of Harvesting, Processing, and Injection Techniques. *Plast Reconstr Surg* 2015;136:897-912.
 6. Chou CK, Lee SS, Lin TY, et al. Micro-autologous Fat Transplantation (MAFT) for Forehead Volumizing and Contouring. *Aesthetic Plast Surg* 2017;41:845-55.
 7. Yun-Nan L, Shu-Hung H, Tsung-Ying L, et al. Micro-autologous fat transplantation for rejuvenation of the dorsal surface of the aging hand. *J Plast Reconstr Aesthet Surg* 2018;71:573-84.
 8. Lin YN, Chuang CH, Huang SH, et al. Fat grafting for resurfacing an exposed implant in lower extremity: A case report. *Medicine (Baltimore)* 2017;96:e8901.
 9. Czerniak S, Gusenoff JA, Peter Rubin J. Commentary: Micro-Autologous Fat Transplantation (MAFT) for Forehead Volumizing and Contouring. *Aesthetic Plast Surg* 2017;41:1093-5.
 10. Lee SS, Huang YH, Lin TY, et al. Long-Term Outcome of Microautologous Fat Transplantation to Correct Temporal Depression. *J Craniofac Surg* 2017;28:629-34.
 11. Kao WP, Lin YN, Lin TY, et al. Microautologous Fat Transplantation for Primary Augmentation Rhinoplasty: Long-Term Monitoring of 198 Asian Patients. *Aesthet Surg J* 2016;36:648-56.
 12. Lin TM, Lin TY, Huang YH, et al. Fat Grafting for Recontouring Sunken Upper Eyelids With Multiple Folds in Asians--Novel Mechanism for Neof ormation of Double Eyelid Crease. *Ann Plast Surg* 2016;76:371-5.
 13. Tang XB, Dong PL, Wang J, et al. Effect of autologous platelet-rich plasma on the chondrogenic differentiation of rabbit adipose-derived stem cells in vitro. *Exp Ther Med* 2015;10:477-83.
 14. Miron RJ, Pinto NR, Quirynen M, et al. Standardization of relative centrifugal forces in studies related to platelet-rich fibrin. *J Periodontol* 2019;90:817-20.
 15. Kobayashi E, Flückiger L, Fujioka-Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig* 2016;20:2353-60.
 16. Li Q, Reed DA, Min L, et al. Lyophilized platelet-rich fibrin (PRF) promotes craniofacial bone regeneration through Runx2. *Int J Mol Sci* 2014;15:8509-25.
 17. Lucarelli E, Beretta R, Dozza B, et al. A recently developed bifacial platelet-rich fibrin matrix. *Eur Cell Mater* 2010;20:13-23.
 18. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006;101:e45-50.
 19. Harris AL. Hypoxia--a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002;2:38-47.
 20. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. *Annu Rev Pathol* 2014;9:47-71.
 21. Li DQ, Lu GM, Liang YD, et al. CD54+ rabbit adipose-derived stem cells overexpressing HIF-1 α facilitate vascularized fat flap regeneration. *Oncotarget* 2017;8:46875-90.
 22. Conley SM, Hickson LJ, Kellogg TA, et al. Human Obesity Induces Dysfunction and Early Senescence in Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells. *Front Cell Dev Biol* 2020;8:197.
 23. Kakudo N, Shimotsuma A, Kusumoto K. Fibroblast growth factor-2 stimulates adipogenic differentiation of human adipose-derived stem cells. *Biochem Biophys Res Commun* 2007;359:239-44.
 24. Kakudo N, Minakata T, Mitsui T, et al. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. *Plast Reconstr Surg* 2008;122:1352-60.
 25. Kakudo N, Kushida S, Suzuki K, et al. Effect of C3 transferase on human adipose-derived stem cells. *Hum Cell* 2011;24:165-9.
 26. Cun X, Xie J, Lin S, et al. Gene profile of soluble growth factors involved in angiogenesis, in an adipose-derived stromal cell/endothelial cell co-culture, 3D gel model. *Cell Prolif* 2015;48:405-12.
 27. Yu P, Zhai Z, Lu H, et al. Platelet-Rich Fibrin Improves Fat Graft Survival Possibly by Promoting Angiogenesis and Adipogenesis, Inhibiting Apoptosis, and Regulating Collagen Production. *Aesthet Surg J* 2020;40:NP530-45.
 28. Xiong S, Qiu L, Su Y, et al. Platelet-Rich Plasma and Platelet-Rich Fibrin Enhance the Outcomes of Fat Grafting: A Comparative Study. *Plast Reconstr Surg* 2019;143:1201e-12e.

29. Wei H, Gu SX, Liang YD, et al. Nanofat-derived stem cells with platelet-rich fibrin improve facial contour remodeling and skin rejuvenation after autologous structural fat transplantation. *Oncotarget* 2017;8:68542-56.
30. Law B, Mohd Yunus SS, Ramli R. Autogenous free fat graft combined with platelet-rich fibrin heals a refractory mandibular osteoradionecrosis. *Clin Ter* 2020;171:e110-3.
31. Liu B, Tan XY, Liu YP, et al. The adjuvant use of stromal vascular fraction and platelet-rich fibrin for autologous adipose tissue transplantation. *Tissue Eng Part C Methods* 2013;19:1-14.
32. Yang YY, Lee PC, Huang YT, et al. Involvement of the HIF-1 α and Wnt/ β -catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury. *Clin Sci (Lond)* 2014;126:163-74.
33. Kakudo N, Morimoto N, Ogawa T, et al. Hypoxia enhances proliferation of human adipose-derived stem cells via HIF-1 α activation. *PLoS One* 2015;10:e0139890.
34. Fan M, Li X, Gao X, et al. LPS Induces Preeclampsia-Like Phenotype in Rats and HTR8/SVneo Cells Dysfunction Through TLR4/p38 MAPK Pathway. *Front Physiol* 2019;10:1030.
35. Kim J, Park M, Jeong W, et al. Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. *Plast Reconstr Surg* 2019;144:619e-29e.
36. Lu F, Li J, Gao J, et al. Improvement of the survival of human autologous fat transplantation by using VEGF-transfected adipose-derived stem cells. *Plast Reconstr Surg* 2009;124:1437-46.
37. Li L, Pan S, Ni B, et al. Improvement in autologous human fat transplant survival with SVF plus VEGF-PLA nano-sustained release microspheres. *Cell Biol Int* 2014;38:962-70.
38. Diepenbrock RM, Green JM 3rd. Autologous Fat Transfer for Maxillofacial Reconstruction. *Atlas Oral Maxillofac Surg Clin North Am* 2018;26:59-68.
39. Liao HT, James IB, Marra KG, et al. The Effects of Platelet-Rich Plasma on Cell Proliferation and Adipogenic Potential of Adipose-Derived Stem Cells. *Tissue Eng Part A* 2015;21:2714-22.

Cite this article as: Huang H, Tang X, Li S, Huang D, Lu D, Wu F, Liu D, Li H. Advanced platelet-rich fibrin promotes the paracrine function and proliferation of adipose-derived stem cells and contributes to micro-autologous fat transplantation by modulating *HIF-1 α* and *VEGF*. *Ann Transl Med* 2022;10(2):60. doi: 10.21037/atm-21-6812